



In the Claims

1. (Withdrawn and currently amended) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has repeating units of the following structure:



wherein the non-fluorinated block has repeating units of the following structure:



wherein R_1 is selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, naphthyl, $-\text{COOR}_3$, and $-\text{CONR}_3\text{R}_4$;



wherein R_2 is selected from the group consisting of $-\text{H}$, $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, and ~~naphthalenyl~~ naphthyl; and

wherein R_3 and R_4 are selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{PEG}$;

~~wherein n is a positive integer; and~~

~~wherein m is a positive integer.~~

2. (Withdrawn and currently amended) The block copolymer of claim 1 having a formula comprising three blocks, the middle block having repeating units of the following structure:



wherein R_1 is selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{PEG}$,

wherein R_2 is selected from the group consisting of $-\text{H}$ or $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{phenyl}$ and $-\text{naphthyl}$,

wherein n is a positive integer; and


wherein m is a positive integer.

3. (Withdrawn) The block copolymer of claim 2 wherein R_1 is $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, or $-\text{PEG}$, and

wherein R_2 is $-\text{H}$ or $-\text{CH}_3$.

4. (Withdrawn and currently amended) A block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block


has repeating units of the following structure:




wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof; and

wherein n is a positive integer.

5. (Withdrawn and currently amended) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has repeating units of the following structure:



wherein the non-fluorinated block has repeating units of the following structure:



wherein R_1 is selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, naphthyl, $-\text{COOR}_3$, and $-\text{CONR}_3\text{R}_4$;

wherein R_2 is selected from the group consisting of $-\text{H}$, $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, -



$\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, and ~~naphthalenyl~~ naphthyl; and

wherein R_3 and R_4 are selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{PEG}$;

~~wherein n is a positive integer; and~~

~~wherein m is a positive integer.~~

6. (Withdrawn and currently amended) The coating composition of claim 5 wherein the block copolymer has a formula comprising three blocks, the middle block having repeating units of the following structure:



wherein R_1' is selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{PEG}$, and

wherein R_2 is selected from the group consisting of $-\text{H}$ or $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$,

-CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -phenyl and naphthyl,


~~wherein n is a positive integer, and~~

~~wherein m is a positive integer.~~

7. (Withdrawn) The coating composition of claim 6 wherein R₁ is selected from the group consisting of -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH₂CH₂OH, or -PEG, and

wherein R₂ is -H or -CH₃.

8. (Withdrawn and currently amended) A polymeric coating composition comprising a block copolymer which comprises a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block has repeating units of the following structure:



wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof; and

~~wherein n is a positive integer.~~

9. (Withdrawn) The coating composition of claim 5 further comprising a bioactive agent.

10. (Withdrawn) The coating composition of claim 6 further comprising a bioactive agent.

11. (Withdrawn) The coating composition of claim 7 further comprising a bioactive agent.

12. (Withdrawn) The coating composition of claim 8 further comprising a bioactive agent.


13. (Withdrawn) The coating composition of claim 9 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

14. (Withdrawn) The coating composition of claim 10 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.


15. (Withdrawn) The coating composition of claim 11 wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, Everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

16. (Previously presented) An implantable device comprising a coating which comprises a block copolymer, the block copolymer comprising a fluorinated block and at least one non-fluorinated block, wherein the fluorinated block is a poly(fluoroalkene).

17. (Currently amended) The implantable device of claim 16, wherein the fluorinated block has repeating units of the following structure:



wherein the non-fluorinated block has repeating units of the following structure:



wherein R_1 is selected from the group consisting of $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, naphthyl, $-\text{COOR}_3$, and $-\text{CONR}_3\text{R}_4$;


wherein R_2 is selected from the group consisting of $-\text{H}$, $-\text{CH}_3$, $-\text{CF}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, -phenyl, and ~~naphthalenyl~~ naphthyl; and


wherein R_3 and R_4 are selected from the group consisting of $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_3$, $-\text{CH}_2\text{CH}_2\text{OH}$, and $-\text{PEG}$;

wherein n is a positive integer; and


wherein m is a positive integer.

18. (Currently amended) The implantable device of claim 17, wherein the block copolymer has a formula comprising three blocks, the middle block having repeating units of the following structure:





H' H F' CF₃, and the two end blocks having repeating units of the
following structure



wherein R₁' is selected from the group consisting of -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH₂CH₂OH, and -PEG, and

wherein R₂ is selected from the group consisting of -H or -CH₃, -CF₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -phenyl and naphthyl;


~~wherein n is a positive integer, and~~

~~wherein m is a positive integer.~~

19. (Previously presented) The implantable device of claim 18 wherein R₁' is selected from the group consisting of -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH₂CH₂OH, and -PEG, and

wherein R₂ is -H or -CH₃.

20. (Currently amended) The implantable device of claim 16, wherein the fluorinated block has repeating units of the following structure:



wherein the non-fluorinated block is a polymer selected from the group consisting of polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, and a combination thereof; and

~~wherein n is a positive integer.~~

21. (Original) The implantable device of claim 16, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

22. (Original) The implantable device of claim 17, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

23. (Original) The implantable device of claim 18, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

24. (Original) The implantable device of claim 19, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

25. (Original) The implantable device of claim 20, which is a drug-eluting stent, wherein the coating further comprises a bioactive agent.

26. (Previously presented) The implantable device of claim 21, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

27. (Previously presented) The implantable device of claim 22, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

28. (Previously presented) The implantable device of claim 23, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

29. (Previously presented) The implantable device of claim 24, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

30. (Previously presented) The implantable device of claim 25, wherein the bioactive agent is selected from the group consisting of tacrolimus, dexamethasone, rapamycin, everolimus, 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.

31. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 16.

32. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 17.

33. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim 26.



34. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim

27.

35. (Withdrawn) A method of treating restenosis or vulnerable plaque, comprising implanting in a human being in need thereof the implantable device of claim

28.

36. (Withdrawn and currently amended) A method of synthesizing a block copolymer comprising a fluorinated block and at least a block having repeating units of the following structure:



in the presence of a di-halo macromer,

wherein R₁ is selected from the group consisting of -CH₃, -CF₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -phenyl, naphthyl, -COOR₃, and -CONR₃R₄;

wherein R₂ is selected from the group consisting of -H, -CH₃, -CF₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -phenyl, and ~~naphthalenyl~~ naphthyl;

wherein R₃ and R₄ are selected from the group consisting of -CH₃, -CH₂CH₃, -CH₂CH₂CH₃, -CH₂CH₂CH₂CH₃, -CH₂CH₂OH, and -PEG; and

wherein the di-halo macromer is selected from the group consisting of di-chloro macromer, di-bromo macromer, di-iodo macromer and a combination thereof;

~~wherein n is a positive integer, and~~


wherein m is a positive integer.

37. (Withdrawn) The method of claim 36 wherein the di-halo macromer is formed by polymerizing a fluorinated olefin in the presence of a dihalide.

38. (Withdrawn) The method of claim 37 wherein the fluorinated olefin is selected from the group consisting of vinylidene fluoride, hexafluoropropylene, tetrafluoroethylene, and a combination thereof.

39. (Withdrawn) The method of claim 38 wherein the di-halo macromer is prepared by polymerizing a mixture of vinylidene fluoride and 1,1,2,3,3,3-hexafluoropropylene in the presence of 1,2-diiodo-1,1,2,2-difluoroethylene.

40. (Withdrawn and currently amended) The method of claim 39 the di-halo macromer has repeating units of a structure of



positive integer.